Neoadjuvant Treatment versus Upfront Surgery in Resectable Pancreatic Cancer: Clinical Significance of Portal Vein and Superior Mesenteric Vein Contact and Associated Prognostic Factors

H.S Kim,M Lee,H.J Sohn,Y.H Kang,Y Han,J.S Kang,W Kwon,J.-Y Jang

doi:10.1016/j.hpb.2022.05.592

Neoadjuvant Treatment versus Upfront Surgery in Resectable Pancreatic Cancer: Clinical Significance of Portal Vein and Superior Mesenteric Vein Contact and Associated Prognostic Factors

H.S Kim, M Lee + Show 6 more

Open Access

https://doi.org/10.1016/j.hpb.2022.05.592

Copy DOI

Journal: HPB : the official journal of the International Hepato Pancreato Biliary Association	Publication Date: Jan 1, 2022
License type: publisher-specific-oa

Affiliation: Seoul National University

#Resectable Pancreatic Ductal Adenocarcinoma Patients #Efficacy Of Neoadjuvant Treatment + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Introduction: The efficacy of neoadjuvant treatment (NAT) in resectable pancreatic ductal adenocarcinoma (PDAC) remained debatable, particularly in portal vein (PV)/superior mesenteric vein (SMV) contact. This study investigated the clinical significance of PV/SMV contact and NAT in resectable PDAC patients.

Full Text